Varex Imaging Outperforms GlucoTrack in Analyst Comparisons

Varex Imaging's stronger consensus rating and higher potential upside make it a more favorable investment, according to analysts.

Feb. 7, 2026 at 3:31am

Got story updates? Submit your updates here. ›

GlucoTrack (NASDAQ:GCTK) and Varex Imaging (NASDAQ:VREX) are both small-cap medical companies, but analysts believe Varex Imaging is the superior investment. The analysis compares the two companies on factors like earnings, valuation, profitability, analyst recommendations, and institutional ownership. Varex Imaging scores better on 9 out of 13 factors, including having a stronger consensus rating from analysts and higher potential upside.

Why it matters

This analysis provides valuable insights for investors looking to compare these two medical technology companies and make informed decisions about which one may be the better investment. The findings highlight Varex Imaging's relative strengths compared to GlucoTrack, which could be important considerations for those seeking growth opportunities in the small-cap medical device sector.

The details

The analysis found that Varex Imaging has stronger net margins, return on equity, and return on assets compared to GlucoTrack. Varex Imaging also has a consensus price target of $16.17, indicating a potential upside of 15.48%, while analysts are more bullish on Varex Imaging overall based on their ratings. Additionally, Varex Imaging has stronger institutional ownership at 10.9% versus 4.6% for GlucoTrack, suggesting greater support from large investors.

  • The analysis was published on February 7, 2026.

The players

GlucoTrack, Inc.

A medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States.

Varex Imaging Corporation

A company that designs, manufactures, and sells X-ray imaging components for use in a range of medical and industrial applications.

Got photos? Submit your photos here. ›

The takeaway

This analysis highlights Varex Imaging's relative strengths compared to GlucoTrack, with Varex Imaging scoring better on key metrics like profitability, analyst recommendations, and institutional ownership. For investors looking to gain exposure to the small-cap medical device sector, Varex Imaging appears to be the more favorable investment option based on the findings.